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OBJECTIVES The purpose of this study was to evaluate the effect of abciximab use on clinical outcome in
aortocoronary vein graft interventions.
BACKGROUND Although large randomized trials have demonstrated a significant benefit of abciximab use in
the setting of percutaneous coronary interventions, there is relatively little data with respect
to the use of this agent in percutaneous vein graft interventions.
METHODS Three hundred and forty-three patients were identified; 210 undergoing vein graft interven-
tion without abciximab and 133 patients with abciximab.
RESULTS There were differences in baseline clinical and angiographic characteristics between the two
groups; advanced age, unstable angina, older vein grafts and thrombus containing lesions were
relatively common in both groups. Angiographic and procedural success rates were similar
with or without the use of abciximab (89% vs. 92%, p 5 0.15, and 85% vs. 91%, p 5 0.12,
respectively). The in-hospital composite end point of death/Q-wave myocardial infarction
(QWMI)/repeat revascularization was similar between the two groups. Utilizing statistical
modeling to adjust for baseline differences between the groups, abciximab use did not
influence the cumulative long-term composite end point of death/MI/repeat revasculariza-
tion.
CONCLUSIONS This study demonstrates that in this relatively high-risk population undergoing aortocoronary
vein graft interventions, the administration of abciximab periprocedurally does not appear to
reduce major adverse clinical events. (J Am Coll Cardiol 1999;34:1163–9) © 1999 by the
American College of Cardiology
Aortocoronary vein graft failure is relatively frequent during
the course of long-term follow-up after coronary artery
bypass graft surgery (CABG) (1–4). Repeat CABG in such
patients is associated with an increased rate of periproce-
dural death and myocardial infarction (MI) (5–7), reduced
graft patency (5) and decreased event-free survival (8,9).
Therefore, an increasing number of patients with vein graft
disease with recurrent ischemia are referred for percutaneous
intervention. Percutaneous vein graft intervention can be
performed with a relatively high rate of angiographic suc-
cess, although distal embolization and poor reflow culmi-
nating in MI occurs more commonly than with native
coronary interventions (10–12). In addition, restenosis after
percutaneous transluminal coronary angioplasty (PTCA) of
vein graft disease is substantial (13,14), although it may be
improved by the use of stents (15,16).
Whether other adjunctive therapies may reduce the rel-
atively high short- and long-term adverse event rates in
patients undergoing vein graft interventions remains to be
seen. The platelet glycoprotein IIb-IIIa receptor antagonist,
abciximab, has been shown to reduce adverse events in
patients undergoing percutaneous revascularization, initially
in high-risk subsets (17,18) and later in a broader spectrum
of patients (19). However, bypass graft interventions were
performed on a minority of cases in the randomized trials of
this agent. Therefore, the question remains as to whether
abciximab may offer a benefit in the high-risk lesion subset
of vein graft interventions.
The purpose of this study was to evaluate our recent
experience with vein graft interventions and to evaluate the
influence of abciximab use on clinical outcome in such
procedures.
METHODS
The study protocol was approved by the Mayo Clinic
Institutional Review Board. We reviewed our institutional
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coronary interventional database from January 1, 1995
through December 31, 1997 and identified all patients
undergoing percutaneous intervention involving at least one
aortocoronary venous bypass graft and subdivided these into
patients receiving abciximab periprocedurally and those who
did not. Follow-up information in this database is obtained
in a prospective fashion. For all patients, baseline demo-
graphic information, procedural, lesional and angiographic
data acquired during the case were reviewed.
Definitions. Acute myocardial infarction was considered to
have occurred when at least two of the following three
criteria were met: 1) chest pain .30 min, 2) persistent
electrocardiographic changes suggestive of ischemia or 3)
characteristic elevations in serum creatine kinase levels with
a corresponding rise in the MB isoform within 24 h of the
procedure. Multivessel disease was defined as the presence
of $70% stenosis of the luminal diameter in a major
epicardial coronary artery with $50% stenosis in a second
major epicardial vessel (2 vessel disease) or both of the other
epicardial vessels (3 vessel disease). Angiographic success
was defined as a $20% improvement in diameter stenosis
with a #50% residual diameter stenosis. Procedural success
was defined as an angiographically successful procedure
without in-hospital, death, Q-wave MI or CABG. Proce-
dural risk as assessed by the operator in our database was
categorized as low, intermediate or high and incorporated
clinical and angiographic characteristics including patient
age, multivessel disease, left ventricular function, presence
or absence of unstable angina, lesion length, presence or
absence of intralesional thrombus and age of the vein graft
treated. Comorbid conditions including significant pulmo-
nary disease, renal insufficiency and significant vascular
disease were also considered.
Angioplasty technique for stent implantation. All angio-
plasty procedures were performed using standard techniques
as described previously (20). Intracoronary stent implanta-
tion techniques evolved over the study period. Premounted
coronary stents or hand-crimped peripheral/biliary stents
were generally placed across target lesions using 0.014-in.
extra support guide wires for delivery. Delivery balloons
were inflated to nominal pressure. As of 1994, stent delivery
has been routinely followed by high pressure ($14 atmo-
spheres) balloon inflations using noncompliant or minimally
compliant balloons at sizes equivalent to or slightly larger
than nominal stent size with the goal of achieving a residual
diameter stenosis of 0%. Intravascular ultrasound was used
to guide stent deployment at the discretion of the operator.
Anticoagulation. All patients received preprocedural oral
aspirin (325 mg) and received intraprocedural heparin.
Heparin was discontinued after the procedure, and sheaths
were removed when the activated clotting time (ACT) was
,160 s. Heparin was resumed after sheath removal and
continued until the target international normalized ratio was
achieved. Between late 1994 and early 1995, warfarin was
administered to patients with suboptimal stent deploy-
ment as assessed by coronary angiography or intravascular
ultrasonography, with standard post-stent therapy con-
sisting of ticlopidine 250 mg twice daily for four to six
weeks and aspirin 81 to 325 mg daily. In patients
receiving only antiplatelet therapy postprocedure, no
further heparin was administered postprocedure. Later,
warfarin was completely eliminated and patients believed
to be at increased risk for subacute stent occlusion received
subcutaneous injections of low molecular weight heparin
30 mg or 60 mg b.i.d. for 10 to 14 days in addition to aspirin
and ticlopidine.
Statistical analysis. Baseline characteristics are presented
as mean values with standard deviation or as a percentage of
total patients with available data in each group. Pearson’s
chi-square test for discrete variables and Student t test for
continuous variables were used for comparisons.
A logistic regression model utilizing a forward stepwise
variable selection process was developed to determine which
clinical and angiographic variables were associated with
abciximab use for vein graft interventions in our database.
Logistic regression models and Cox proportional hazard
models were developed to assess the relationship between
abciximab use and in-hospital and follow-up events, respec-
tively. These models were developed in two different ways.
First, a propensity score was calculated from the coefficients
of the logistic regression model that utilized abciximab use
as an end point. The propensity score was intended to adjust
for baseline factors that may have influenced the operator’s
decision to utilize abciximab. Also, forward stepwise regres-
sion procedures were used including clinical and angio-
graphic variables; the use of abciximab was then added to
these models.
These models were used to calculate odds ratios (ORs)
Abbreviations and Acronyms
ACC/AHA 5 American College of
Cardiology/American Heart Association
ACT 5 activated clotting time
CABG 5 coronary artery bypass grafting
CAPTURE 5 Chimeric 7E3 Antiplatelet in Unstable
Angina Refractory to Standard Treatment
CI 5 confidence interval
CPK 5 creatine phosphokinase
EPIC 5 Evaluation of c7E3 in Preventing Isch-
emic Complications
EPILOG 5 Evaluation of PTCA to Improve Long-
Term Outcomes by c7E3 Glycoprotein
IIB/IIIA Receptor Blockade
MI 5 myocardial infarction
NQWMI 5 non-Q-wave myocardial infarction
OR 5 Odds ratio
PTCA 5 percutaneous transluminal coronary
angioplasty
TIMI 5 Thrombolysis in Myocardial Infarction
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for abciximab use for the in-hospital composite end point of
death/Q-wave MI/repeat revascularization (repeat PTCA
of the target lesion or CABG) and risk ratios for the
cumulative long-term end point of death/MI/repeat revas-
cularization from the time of procedure onward, which
included in-hospital events as well. Adjusted survivals were
calculated from the Cox models fixing the coefficients for
the other covariates at their means and varying the coeffi-
cient for abciximab.
Results of these analyses were similar utilizing either the
propensity score model or the forward stepwise regression
model; therefore, data are presented from the latter.
RESULTS
Baseline and clinical characteristics. During the specified
study period, 343 patients undergoing aortocoronary vein
graft interventions were identified; 210 without abciximab
and 133 with abciximab administered periprocedurally.
Baseline clinical characteristics are shown in Table 1.
Patients receiving abciximab were slightly older (70 6 9 yr
vs. 68 6 9 yr, p 5 0.03), had older vein grafts (9.6 6 4.4 yr
vs. 7.9 6 4.9 yr, p 5 0.001) and a higher incidence of prior
MI (77.1% vs. 66.7%, p 5 0.04), although the rates of acute
MI on presentation were similar between the two groups
(12.8% vs. 9.0%, p 5 0.27). Patients receiving abciximab
were less likely to present with unstable angina (70.7% vs.
81.4%, p 5 0.02).
Of the patients receiving abciximab periprocedurally, the
agent was initiated before the first balloon inflation (or
before beginning the intervention in non-PTCA cases) in
85 (63.9%), whereas in 48 patients (36.1%), abciximab was
initiated during the procedure sometime after the initiation
of the intervention. Additionally, patients receiving abcix-
imab were more likely to be considered a high-risk proce-
dure by the operator performing the procedure (48.9% vs.
33.3%, p 5 0.004).
Lesion/procedural characteristics. Lesion and procedural
characteristics of the two groups are shown in Table 2. The
patients receiving abciximab were more likely to have
received a stent during the course of their procedure (84%
vs. 75%, p 5 0.04). The frequency of concomitant native
vessel interventions, coronary territory supplied by the
treated graft and treatment site within the graft were similar
between the two groups. Patients receiving abciximab were
more likely to have angiographic evidence of intragraft
thrombus (66% vs. 40%, p , 0.001) and were more likely to
Table 1. Baseline Clinical Characteristics
Characteristic
No Abciximab
n 5 210
Abciximab
n 5 133
p
Value
Age (yr) 68 6 9 70 6 9 0.03
Men (%) 163 (77.6) 109 (82.0) 0.33
Smoking
Current 22 (10.6) 16 (12.0) 0.68
Previous 120 (57.7) 68 (51.1) 0.24
Diabetes 79 (37.6) 38 (28.6) 0.09
Hypertension 144 (69.2) 97 (73.5) 0.40
Chol .240 mg/dL 148 (76.3) 96 (80.0) 0.44
# Diseased vessels
1 68 (33.8) 35 (27.1) 0.20
2 77 (38.3) 49 (38.0) 0.95
3 56 (27.9) 45 (34.9) 0.18
Time since CABG (yr) 7.9 6 4.9 9.6 6 4.4 0.001
Unstable angina (%) 171 (81.4) 94 (70.7) 0.02
Prior MI 138 (66.7) 101 (77.1) 0.04
Acute MI 19 (9.0) 17 (12.8) 0.27
LVEF (%) 55.3 6 18.1 55.3 6 16.1 0.99
CHF now 28 (13.7) 22 (16.8) 0.44
Data presented as mean 6 SD or number and (%) of patients.
AMI 5 acute myocardial infarction within 24 hours of procedure; CHF 5
congestive heart failure; Chol 5 total serum cholesterol; LVEF 5 left ventricular
ejection fraction at time of procedure.
Table 2. Lesion/Procedural Characteristics
Characteristic
No
Abciximab Abciximab
p
Value
Patients 210 133
Graft lesions treated 244 189 —
Graft stent 157 (75) 112 (84) 0.04
Native PTCA also 52 (25) 28 (21) 0.43
Graft restenosis lesions 22 (9) 10 (5) 0.14
Atherectomy (rotational,
directional or extractional)
19 (8) 17 (9) 0.65
Location of graft
LAD 78 (32) 52 (28) 0.32
LCx 97 (40) 77 (41) 0.84
RCA 69 (28) 60 (32) 0.43
Treatment site
Origin 62 (25) 52 (28) 0.62
Body 108 (44) 80 (42) 0.69
Distal 62 (25) 47 (25) 0.90
Total occlusion 12 (5) 10 (5) 0.86
Lesion characteristics
diffuse 57 (23) 37 (20) 0.34
discrete 162 (66) 111 (59) 0.10
thrombus 97 (40) 124 (66) , 0.001
Lesion type
A 0 (0) 2 (1) 0.10
B1 13 (5) 3 (2) 0.04
B2 57 (23) 15 (8) , 0.001
C 163 (67) 155 (82) , 0.001
TIMI flow preprocedure
0 17 (8) 29 (21) , 0.001
1 24 (12) 11 (8) 0.32
2 43 (20) 26 (19) 0.78
3 129 (61) 71 (52) 0.11
TIMI flow postprocedure
0 6 (2) 11 (6) 0.06
1 6 (2) 7 (4) 0.39
2 5 (2) 19 (11) , 0.001
3 224 (93) 139 (79) , 0.001
LAD 5 left anterior descending; LCx 5 left circumflex; PTCA 5 percutaneous
transluminal coronary angioplasty; RCA 5 right coronary artery.
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have American College of Cardiology/American Heart
Association (ACC/AHA) type C lesions (82% vs. 67%, p ,
0.001). Abciximab patients were also more likely to have
Thrombolysis in Myocardial Infarction (TIMI) 0 flow
before the intervention (21% vs. 8%, p , 0.001) and were
less likely to have TIMI 3 flow at the end of the procedure
(79% vs. 93%, p , 0.001).
Of note, newer technologies including directional
atherectomy, extractional atherectomy and rotational
atherectomy were relatively uncommon in both groups.
Postprocedural anticoagulation. Patients receiving abcix-
imab were less likely to receive warfarin upon dismissal
(11.5% vs. 23.4%, p 5 0.006) and were more likely to
receive low molecular heparin upon dismissal (13.1% vs.
6.3%, p 5 0.03).
In-hospital events. Table 3 displays the in-hospital events
of the two groups. Angiographic success was similar with or
without the use of abciximab (89% vs. 92%, p 5 0.15), as
was procedural success (85% vs. 91%, p 5 0.12). The rates
of in-hospital death, Q-wave MI, bypass surgery and repeat
PTCA were similar between the two groups. The in-
hospital composite end point of death/Q-wave MI/repeat
revascularization was also similar between the two groups.
Table 4 displays other in-hospital end points, which were
not included in the prespecified in-hospital composite end
point. Patients receiving abciximab had higher rates of distal
embolization (17% vs. 7%, p 5 0.004), and non-Q-wave
MI (NQWMI) (21.1% vs. 6.7%, p , 0.001). In addition,
patients receiving abciximab were more likely to have a
cerebrovascular event (2% vs. 0%, p 5 0.03) as well as major
bleeding (19% vs. 8%, p 5 0.002), although this series
included our early experience with abciximab, which utilized
standard dose periprocedural heparin therapy.
In patients sustaining an MI, mean creatine phosphoki-
nase (CPK) values were somewhat higher in patients receiv-
ing abciximab (1,454 6 865 IU/L vs. 1,118 6 1,045 IU/L,
p 5 0.051).
Correlates of abciximab use. Table 5 shows the univariate
correlates of periprocedural abciximab use. Patient age as a
continuous variable, prior MI, graft age as a continuous
variable, graft age .5 years, intragraft thrombus, type C
lesion and high-risk procedure were all associated with a
greater likelihood of abciximab use. Other variables includ-
ing diabetes mellitus, multivessel disease, unstable angina,
acute MI, reduced ejection fraction and reduced TIMI flow
preprocedure were not correlated with the utilization of
abciximab.
Multivariate analysis demonstrated that the presence of
intragraft thrombus and type C lesions were correlated with
abciximab use. Graft age .5 years and high-risk procedures
were weakly correlated with the use of abciximab (Table 6).
These variables were incorporated into the propensity score.
Correlates of in-hospital death/Q-wave MI/repeat revas-
cularization. After adjustment for differences in baseline
variables, the variable of high-risk procedure was most
strongly correlated with the occurrence of the prespecified
in-hospital composite end point (OR 3.11, confidence
interval [CI] 1.01–9.55, p 5 0.047). Patient age was weakly
correlated with the occurrence of in-hospital adverse events
(OR 1.06, CI 0.99–1.12, p 5 0.06). The use of periproce-
dural abciximab did not affect in-hospital adverse events
(OR 1.21, CI 0.48–3.04, p 5 0.68) (Table 7).
Table 3. In-Hospital Events
Variable
No
Abciximab Abciximab
p
Value
Patients 210 133 —
Angiographic success 92% 89% 0.15
Procedural success 91% 85% 0.12
Death 7 (3) 9 (7) 0.14
Q-wave MI 4 (2) 2 (2) 0.78
CABG 0 (0) 0 (0) 1.0
Repeat PTCA 1 (0.5) 1 (1) 0.74
Combined end point 11 (5) 12 (9) 0.17
Numbers in parentheses are percentages of total in each group. Combined end
point 5 death, Q-wave MI, CABG or repeat PTCA.
CABG 5 coronary artery bypass grafting; MI 5 myocardial infarction; PTCA 5
percutaneous transluminal coronary angioplasty.
Table 4. In-Hospital Events
Variable No Abciximab Abciximab p Value
NQWMI 14 (6.7) 28 (21.1) , 0.001
Distal embolization 15 (7) 23 (17) 0.004
CVA 0 (0) 3 (2) 0.03
Major bleeding 16 (8) 25 (19) 0.002
Numbers in parentheses are percentages of total in each group.
CVA 5 cerebrovascular accident; NQWMI 5 non-Q-wave myocardial infarction.
Table 5. Univariate Correlates of Abciximab Use
Variable OR CI (95%) p Value
Patient age 1.03 (1.00–1.05) 0.033
Prior MI 1.68 (1.02–2.77) 0.041
Graft age 1.08 (1.03–1.14) 0.001
Graft .5 years 3.15 (1.73–5.75) 0.0002
Thrombus 3.86 (2.37–6.29) 0.0001
Type C lesion 3.37 (1.79–6.35) 0.0002
High-risk procedure 1.91 (1.23–2.98) 0.004
MI 5 myocardial infarction.
Table 6. Multivariate Model for Abciximab Use
Variable OR CI (95%) p Value
Thrombus 2.86 (1.70–4.81) 0.0001
Type C lesion 2.07 (1.04–4.12) 0.038
Graft .5 years 1.94 (0.96–3.94) 0.066
High-risk procedure 1.56 (0.93–2.60) 0.092
CI 5 confidence interval; OR 5 odds ratio.
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Correlates of death/MI/repeat revascularization from the
time of procedure onward. Table 8 demonstrates the
variables associated with the cumulative long-term end
point of death/MI/repeat revascularization from the time of
procedure onward. After adjustment for differences in base-
line characteristics, it appeared that the occurrence of
death/MI/repeat revascularization was correlated with re-
duced TIMI flow pre- or postprocedure (OR 1.96, CI 1.35
to 2.84, p 5 0.0004), multivessel disease (OR 1.57, CI 1.02
to 2.42, p 5 0.04) and was weakly correlated with patient
age (OR 1.02, CI 1.0 to 1.04, p 5 0.063). The use of
abciximab periprocedurally was also weakly correlated with
a greater relative risk of this composite end point during the
course of a long-term follow-up period (OR 1.42, CI 0.96
to 2.10, p 5 0.077) (Fig. 1).
Influence of timing of abciximab administration. In the
current series, 63.9% of patients receiving abciximab had the
agent initiated before the onset of the intervention. Baseline
clinical characteristics were similar in patients receiving
abciximab before the intervention when compared with
those receiving the agent after the intervention began,
except that those receiving abciximab before the procedure
were more likely to present with unstable angina (78.8% vs.
56.3%, p , 0.006) and less likely to present with acute MI
(4.7% vs. 27.1%, p 5 0.002). Procedural success and
in-hospital events of death, Q-wave MI, NQWMI, repeat
PTCA and CABG were similar between the two groups
(Table 9). Distal embolization occurred more commonly in
patients receiving abciximab after the intervention began,
although this difference was not statistically significant
(22.9% vs. 14.1%, p 5 0.20).
To determine the influence of the timing of abciximab
administration on the occurrence of adverse events, multi-
variate analysis was performed incorporating this as a
variable. In this analysis, administration of abciximab before
the intervention was associated with a nonsignificant rela-
tive risk reduction as compared with patients receiving
abciximab sometime after the initiation of the intervention
(adjusted relative risk 0.70, CI 0.41 to 1.20, p 5 0.19).
However, patients receiving abciximab before the initiation
of the intervention had a similar risk of adverse events when
compared with patients not receiving abciximab (adjusted
relative risk 1.05, CI 0.67 to 1.66, p 5 0.83). Because it was
plausible that provisional abciximab (administered after the
balloon inflation) occurred because of unsatisfactory angio-
graphic appearance after initiation of the intervention, we
constructed Kaplan-Meier survival curves for freedom from
death/MI/revascularization from the time of procedure for
patients receiving abciximab before the intervention com-
pared with patients not receiving abciximab at all, adjusting
for differences in baseline clinical and angiographic vari-
ables. In this analysis, there was no difference between
Figure 1. Adjusted survival estimates of freedom from death/MI/
repeat revascularization from the time of procedure onwards with
abciximab versus without abciximab. MI 5 myocardial infarction.
Table 8. Correlates of Death/MI/Repeat Revascularization
From Time of Procedure
OR CI p Value
TIMI ,3 pre- or
postoperation
1.96 (1.33–2.82) 0.0004
Age 1.02 (1.0–1.04) 0.063
Multivessel disease 1.57 (1.02–2.41) 0.043
Abciximab 1.42 (0.97–1.59) 0.077
CI 5 confidence interval; MI 5 myocardial infarction; OR 5 odds ratio; TIMI 5
thrombolysis in myocardial infarction.
Table 9. In-Hospital Events for Patients Receiving Abciximab
Prior to Initiation of Intervention Versus Those Receiving
Abciximab After Initiation of Intervention
Variable
Abciximab Prior
to Initiation of
Intervention
Abciximab
After Initiation
of Intervention
p
Value
Patients 85 48
Procedural success 83.5% 87.5% 0.54
Death 6 (7.1) 3 (6.3) 0.86
Q-Wave MI 1 (1.2) 1 (2.1) 0.68
NQWMI 19 (22) 9 (19) 0.62
CABG 0 0 —
Repeat PTCA 1 0 0.45
Distal
embolization
12 (14.1) 11 (22.9) 0.20
Numbers in parentheses are percentages of total in each group.
CABG 5 coronary artery bypass grafting; MI 5 myocardial infarction;
NQWMI 5 non-Q-wave myocardial infarction; PTCA 5 percutaneous transluminal
coronary angioplasty.
Table 7. Multivariate Model for In-Hospital Death/QWMI/
Repeat Revascularization
OR CI
p
Value
High-risk procedure 3.11 (1.01–9.55) 0.047
Age 1.06 (0.99–1.12) 0.06
Abciximab 1.21 (0.48–3.04) 0.68
CI 5 confidence interval; QWMI 5 Q-wave myocardial infarction; OR 5 odds ratio.
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patients receiving abciximab versus those who did not (Fig.
2).
DISCUSSION
This study represents a recent single-center experience of
aortocoronary vein graft interventions and comprises a
relatively high-risk cohort: advanced age, unstable angina on
presentation, diabetes mellitus, multivessel disease and older
vein grafts with thrombus were frequent in this group. In
this group, utilization of periprocedural abciximab did not
improve the in-hospital composite end point of death/Q-
wave MI/repeat revascularization or the cumulative long-
term end point of death/MI/repeat revascularization.
In the Evaluation of c7E3 in Preventing Ischemic Com-
plications (EPIC) and Chimeric 7E3 Antiplatelet in
Unstable Angina Refractory to Standard Treatment
(CAPTURE) trials, it has been demonstrated that abcix-
imab use was associated with improved clinical outcome
after percutaneous and coronary interventions in high-risk
patients (17,18). Later, the Evaluation of PTCA to Improve
Long Term Outcomes by c7E3 Glycoprotein IIB/IIIA
Receptor Blockade (EPILOG) study confirmed that the
benefit of abciximab in percutaneous coronary interventions
was not necessarily limited to high-risk patients (19).
Furthermore, it has been demonstrated that the benefit of
abciximab was apparent even in the absence of angiographi-
cally apparent thrombus (21).
However, these randomized trials primarily included
patients undergoing native coronary interventions, with a
relatively small proportion of patients with aortocoronary
vein graft interventions; for example, in the EPIC study,
only 4% of patients underwent vein graft interventions. It
has been previously reported that the prophylactic admin-
istration of abciximab before vein graft interventions reduces
the occurrence of distal embolization and NQWMI
periprocedurally (22). Nevertheless, this study is in accord
with recently reported data from the EPIC and EPILOG
trials, which failed to demonstrate a relative risk reduction
with abciximab use in patients undergoing percutaneous
intervention of degenerated saphenous vein grafts (23).
Of note is that there was a greater incidence of distal
embolization and NQWMI in the abciximab group in this
study. However, because 36.3% of patients in this study
receiving abciximab received the agent provisionally (after
the intervention had begun), it is likely that the increase in
distal embolization and NQWMI in this group was due to
adverse angiographic events that had occurred, prompting
administration of abciximab, rather than being the result of
abciximab use. Such “rescue” administration of abciximab
has been demonstrated in an observational study to be
beneficial in patients in whom intracoronary thrombus
developed after PTCA, with no instances of distal emboli-
zation or no reflow in a series of 29 patients (24), although
no vein graft interventions were reported. However, in our
study, even when excluding patients receiving provisional
abciximab, there was no apparent risk reduction in the
composite end points.
Because routine CPK assessment was not performed in
this series, it is possible that “enzyme MI” without apparent
ECG changes or symptoms may have been missed, thereby
underestimating the incidence of NQWMI. Therefore, an
advantage of abciximab use in preventing asymptomatic
enzyme rises cannot be addressed in the current series;
however, recent data suggest that abciximab use is not
protective in preventing CPK elevation after vein graft
intervention (25).
Although atherosclerotic plaques in vein grafts are histo-
logically similar to those found in native coronary athero-
sclerosis, the rates of progression of disease appears to be
accelerated (26). In general, the absolute volume of plaque
and thrombus within a vein graft is greater than that
observed in the native coronary artery; this is particularly
true in older, aneurysmal vein grafts (27,28). This, com-
bined with the fact that a significant component of intralu-
minal filling defects visualized on angiography of vein grafts
may actually represent atherosclerotic debris and organized
thrombus as opposed to acute thrombus, may in part explain
the limited efficacy of abciximab in vein graft disease
demonstrated in this series. It is notable that the use of
abciximab was associated with a slightly higher risk of major
bleeding and cerebrovascular accident, although this in-
cluded our early experience with concomitant high-dose
heparin use.
Study limitations. These data are part of a retrospective
analysis of a single-center database. Because the study is
nonrandomized, it is impossible to determine with certainty
the objective patient and procedural characteristics that
prompted the operator’s decision whether to use abciximab
during the course of the procedure. In addition, patients
receiving abciximab received abciximab at variable times
relative to the beginning of the intervention; however, even
the administration of abciximab prior to the intervention
Figure 2. Adjusted survival estimates of freedom from death/MI/
repeat revascularization from the time of procedure onwards with
pretreatment with abciximab versus without abciximab. MI 5
myocardial infarction.
1168 Mathew et al. JACC Vol. 34, No. 4, 1999
Abciximab in Vein Graft Interventions October 1999:1163–9
did not afford a risk reduction in this series. Furthermore,
asymptomatic CPK rises would have been missed in this
series, although the significance of such increases is a subject
of ongoing debate.
Conclusions. This study demonstrates that, in a relatively
high-risk population undergoing saphenous vein graft in-
terventions with a high preponderance of advanced age,
unstable angina, older vein grafts and thrombus containing
lesions, the administration of abciximab periprocedurally
does not appear to reduce major adverse clinical events.
Given the demonstrated benefits of this agent in other
subsets, this issue may be definitively addressed with a
prospective randomized trial.
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